Immunotherapy response evaluation with F-FDG-PET in patients with advanced stage renal cell carcinoma

Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands, .
World Journal of Urology (Impact Factor: 2.67). 07/2011; 31(4). DOI: 10.1007/s00345-011-0723-y
Source: PubMed


CT imaging is widely used for response evaluation of immunotherapy in patients with advanced stage renal cell carcinoma (RCC). However, this kind of treatment may not immediately be cytoreductive, although the treatment is successful. This poses new demands on imaging modalities. Positron emission tomography (PET) using 18F-fluorodeoxyglucose (FDG) proved to be useful in monitoring the effect of several antitumour treatments. We investigated the potential of FDG-PET for the evaluation of response to immunotherapy.

In seven patients with metastasized RCC, who were treated with either interferon-alpha (IFN-α) monotherapy or a combination of IFN-α, interleukin-2 and 5-fluorouracil, FDG-PET was performed prior and after 5 and 9 weeks of treatment. Quantitative changes of glucose metabolic rate (MRGlu) were compared with changes in tumour size on CT imaging using Response Evaluation Criteria in Solid Tumors (RECIST) and to survival and progression-free survival.

No consistent changes in MRGlu were observed within different response groups. And no correlation with CT imaging, neither with survival or progression-free survival, was found.

In contrast to the positive results reported on (chemo) therapy response evaluation with FDG-PET in different malignancies, this imaging modality appears not useful in response monitoring of immunotherapeutic modalities in RCC.

Download full-text


Available from: Wim J G Oyen, Jan 03, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Most patients treated for lung cancer experience disease recurrence or progression, resulting in high mortality rates. Computed tomography (CT) is central in evaluating treatment response; however, positron emission tomography (PET) may provide a more rapid and prognostically relevant assessment of changes in disease activity during and after treatment. Methods We present a case which illustrates the potential role of PET in assessing treatment response in non-small cell lung cancer (NSCLC) and review the relevant literature. Results A 49-year-old woman presented with an inoperable pancoast tumour of the lung and was treated with radiochemotherapy (RTCT). PET-CT showed that, while her tumour had not changed in size, the metabolic activity of the tumour had decreased significantly following RTCT. The decision was made to resect the tumour, which was found to contain only a small cluster of viable tumour cells. This case illustrates the clinical relevance of assessing metabolic tumour response in addition to morphologic tumour response. Clinical studies have shown PET to be a valuable addition to treatment response assessments performed using CT in a wide range of clinical situations. Following surgical treatment PET is more effective than CT alone in identifying recurrence, and may be useful in differentiating postoperative scar tissue from active tumour. During systemic treatment, whether with chemotherapy or EGFR-TKIs, the early metabolic response seen in PET can be predictive of the degree of clinical benefit. Conclusions In addition to the structural information provided by CT, the metabolic information from PET during or following treatment for NSCLC is increasingly valuable in clinical decision making.
    memo - Magazine of European Medical Oncology 06/2015; 8(2). DOI:10.1007/s12254-015-0213-9